EZHARMIA is the fifth innovative oncology medicine to be launched in Japan by Daiichi Sankyo in the past three years
The newly built centre will work as the state-of-the-art facility for not just ethical animal studies but spans from basic, applied to regulatory animal research.
Her previous role at Novartis, where she was general manager, data & digital, in global drug development, also included accountability for driving the DCT strategy, programs and platforms
CINRYZE is plasma-derived C1-I NH approved for routine prevention (prophylaxis), short-term prevention or pre-procedure prevention, and acute attacks of HAE.
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
The MOU will involve product collaboration from both companies with a goal of propelling PFAS destruction in groundwater globally
This partnership stemmed from a successful customer-supplier relationship spanning several years.
The Institute will focus on increasing preparedness and laboratory capabilities for identification of novel and unknown zoonotic agents
The funds raised through the issue will be utilised to meet the working capital requirements to fund the company's expansion plans, entering new geographies and for general corporate purposes
GMP-compliant documentation of all manufacturing steps for cell and gene therapies
Subscribe To Our Newsletter & Stay Updated
